EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Huntington's disease clinical trials update: August 2026

Mena Farag iD, Opeyemi Kinyomi, Sarah J Tabrizi, Edward J Wild

Journal of Huntington's Disease · 2026-11 · 15 (4) · 543-562

DOI: 10.1177/18796397261499360 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Huntington's Disease, online erschienen am 19.10.2026. Verfasst von Mena Farag und 3 weiteren Autor:innen. Beteiligte Einrichtung: Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK. Hauptthemen laut MEDLINE: Huntington Disease, Clinical Trials as Topic, Oligonucleotides, Antisense. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this edition, we highlight several important developments across the Huntington's disease therapeutic pipeline. We discuss the launch and subsequent discontinuation of POINT-HD, the first-in-human phase I study of RG6496 (Hoffmann-La Roche), an allele-selective antisense oligonucleotide designed to selectively lower mutant huntingtin while largely preserving wild-type huntingtin expression. We also discuss the launch of two phase III efficacy trials: INVEST-HD, evaluating votoplam (Novartis Pharmaceuticals), and PRECISE-HD, evaluating pridopidine (Prilenia). In addition, we summarise recent advances across the field, including preclinical updates for LQT-23 (LoQus23), SRP-1005 (Sarepta Therapeutics) and HRN001 (Harness Therapeutics); interim 12-month clinical results from SKY-0515 (Skyhawk Therapeutics); the announcement by uniQure that 3-year data from the phase I/II AMT-130 study may support a Biologics License Application seeking accelerated approval and Roche's discontinuation of the phase II GENERATION HD2 study of tominersen. Finally, we provide an updated listing of registered and ongoing clinical trials in Huntington's disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseClinical Trials as TopicOligonucleotides, AntisenseHumansAnimals

Stichwörter der Autor:innen

Huntington’s diseaseclinical trials

Substanzen

Oligonucleotides, Antisense

Autor:innen und Institutionen

  • Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK.

ORCID-Profile: Mena Farag

Zitieren

APA

Farag, M., Kinyomi, O., Tabrizi, S. J., & Wild, E. J. (2026). Huntington's disease clinical trials update: August 2026. Journal of Huntington's Disease, 15(4), 543-562. https://doi.org/10.1177/18796397261499360

Vancouver

Farag M, Kinyomi O, Tabrizi SJ, Wild EJ. Huntington's disease clinical trials update: August 2026. Journal of Huntington's Disease. 2026;15(4):543-562. doi:10.1177/18796397261499360

BibTeX
@article{Farag2026,
  author = {Farag, Mena and Kinyomi, Opeyemi and Tabrizi, Sarah J and Wild, Edward J},
  title = {Huntington's disease clinical trials update: August 2026},
  journal = {Journal of Huntington's Disease},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {543--562},
  doi = {10.1177/18796397261499360}
}
Kostenlos starten →